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Summary
 
The introduction of very sensitive HLA antibody screen-
ing assays has destroyed the old dogma that pre-existence
of donor speciﬁc HLA antibodies in the patient is a contra-
indication for transplantation. The challenge is now to
reach consensus on the parameters which predict the clin-
ical relevance of donor speciﬁc HLA antibodies. Antibody
screening assays should not only be used to prevent trans-
plantation of patients with donor speciﬁc antibodies but
also to facilitate transplantation of highly sensitized
patients, both by deﬁning acceptable HLA mismatches
and non-detrimental donor speciﬁc HLA antibodies.
In this issue, David Eckels discusses the clinical implications
of solid-phase human leucocyte antigen (HLA) antibody
testing for organ transplantation (Eckels, 2008).
Although the manuscript was considered too contro-
versial according to American standards, it is an excellent
basis for discussions on this important topic and, hopefully,
will stimulate international collaboration aiming at
solving the many issues, which are not supported by solid
scientiﬁc evidence yet. Actually, many of the points raised
in this discussion paper are not controversial at all and
some of them even common use in many transplantation
programs in Europe and particularly within Eurotransplant.
Since the introduction of very sensitive luminex-based
assays by commercial companies, both HLA laboratories
and clinicians are confused. They were all educated by the
old dogma that donor-speciﬁc antibodies are always a
contraindication for transplantation (Patel & Terasaki,
1969) and many of them immediately gave a similar value
to antibodies detected by these newly developed assays.
However, it is clear that this dogma is not valid anymore,
and the pretransplant assessment of donor-reactive
HLA-speciﬁc antibodies should rather be considered as a
parameter for the risk of adverse complications after
transplantation (Gebel 
 
et al
 
., 2003). Within Eurotransplant
the standard cross-match is still the original complement-
dependent cytotoxicity (CDC) assay, known to be
clinically relevant. Many American colleagues consider
this approach as not ethical (even reviewers of our papers
make such remarks) but transplant results in (highly)
sensitized patients are at least as good in Europe compared
to the USA (Doxiadis 
 
et al
 
., 2005). On the other hand,
complicated and very expensive desensitization programs
are applied by different centres in the USA in order to
transplant ‘sensitized’ patients after removal of antibodies,
which are not detectable in CDC and, until recently, not
even monitored in Europe. Desensitization is probably
useful for a proportion but certainly not for all patients
included in these programs.
A recent retrospective study in highly sensitized
patients, transplanted on the basis of a negative CDC cross-
match, showed that the presence of non-complement ﬁxing
donor-speciﬁc antibodies detected by luminex is associated
with a (treatable) rejection in only a subpopulation of
patients while many patients with donor-speciﬁc antibodies
only detectable in luminex have an excellent long-term
kidney graft survival (van den Berg-Loonen 
 
et al
 
., 2008).
The challenge is, as stated by David Eckels, to dis-
criminate clinically relevant from non-clinically relevant
antibodies. In order to do so, it is essential to deﬁne the
actual speciﬁcities of the antibodies present in the serum
of a patient. Preferentially, one should be able to explain
these speciﬁcities by a previous sensitizing event in the
history of the patient. In the current era with our increased
knowledge of the antibody epitopes present on the HLA
antigens (Duquesnoy, 2006; El-Awar 
 
et al
 
., 2007), this is
feasible. However, the problem is that many centres do
accept all speciﬁcities generated by the computer pro-
grams linked to the commercial screening assays without
evaluating whether these antibody speciﬁcities make any
sense, immunologically speaking.
As already stated by David Eckels, luminex-based
assays from different companies may generate different
antibody speciﬁcities, which is clearly an argument to
look critically at the results. One of the reasons why not
all antibody speciﬁcities are relevant is the fact that these
assays are based on antibody binding to isolated HLA
molecules, which may have a different conformation
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than the HLA molecules naturally expressed on the cell
membrane of the donor organ.
But even the presence of well-deﬁned donor-speciﬁc
HLA antibodies is certainly not always a contraindication
for transplantation. On one hand, these antibodies may
lead to hyperacute or early acute humoral rejection but, on
the other hand, they may be associated with no negative
clinical effect (van den Berg-Loonen 
 
et al
 
., 2008) or even
an enhanced graft survival (Koka 
 
et al
 
., 1993).
The challenge is to preassess the risk associated with the
presence of donor-speciﬁc antibodies and to use this
knowledge for donor selection and/or the immuno-
suppressive policy around or after transplantation.
I do not agree with the statement of David Eckels that
we should drop the CDC test as, in contrast to antibodies
detected by the other very sensitive assays, a positive CDC
cross-match due to donor HLA-speciﬁc IgG antibodies is
known to be clinically relevant in the majority of the
cases. As long as we do not agree on the relevance of all
the other assays, a standard CDC cross-match is helpful to
prevent transplantation of patients with detrimental
donor-speciﬁc HLA antibodies. The next necessary step is
to start international collaboration to determine the
clinical relevance of all the different types of antibodies.
Although several reports show the presence of HLA-C,
-DQA, -DQB, -DPA and -DPB antibodies in potential trans-
plant recipients (i.e. Duquesnoy 
 
et al
 
., 2008), no systematic
analysis of their clinical relevance has been performed
and as a consequence many completely different local
policies are used in patients with these types of antibodies.
Both the expression of the target molecules in the trans-
planted organ and the titre and immunoglobulin class (or
subclass) may play a determinative role in this aspect.
The basis of our decision-making should be antibody
speciﬁcity and not percentage panel reactive antibodies
(%PRA) as it has been for years. The old deﬁnition of
percentage PRA (just based on antibody reactivity against
a panel) must disappear and percentage PRA should be
based on antibody speciﬁcities in combination with the
frequency of the target antigens in the donor population.
Actually, such an algorithm has been introduced in
Eurotransplant.
In the future, one should be able to calculate two types
of PRA: ﬁrst, percentage PRA on the basis of antibodies,
which are a contraindication for transplantation, and
second, percentage PRA on the basis of antibodies, which
should be taken into consideration with respect to the choice
of immunosuppressive treatment if the patient underwent
transplantation despite the presence of these antibodies.
Although knowledge of antibody speciﬁcities is impor-
tant, even more important is a reliable deﬁnition of
acceptable mismatches, those HLA antigens towards the
patient never made a (potentially detrimental) antibody
response. Donor selection based on acceptable mismatches
has shown to be a very efﬁcient tool to enhance transplan-
tation of highly sensitized patients within Eurotransplant
(Claas 
 
et al
 
., 2004). If the future deﬁnition of acceptable
mismatches is based on very sensitive luminex assays, one
can even consider transplanting highly sensitized patients
without performing a pretransplant cross-match provided
that donor and recipient are typed at a high resolution
level, thereby excluding a possible effect of allele-speciﬁc
HLA antibodies.
It is clear that the introduction of solid-phase HLA
antibody tests has had a tremendous impact on the ﬁeld of
histocompatibility testing. What is currently lacking is
consensus on the relevance of the different types of donor-
speciﬁc antibodies for donor selection (which antibodies
are a contraindication for transplantation) and for immu-
nosuppressive treatment (which antibodies are associated
with treatable early acute humoral rejection).
It is essential to use the results of antibody screening
assays not only to prevent transplantation of patients but
to facilitate transplantation of (highly) sensitized patients
on basis of acceptable mismatches or in the presence of
clinically non-detrimental donor-speciﬁc HLA antibodies.
Routinely monitoring the appearance of donor-speciﬁc
antibodies after transplantation may be an additional tool
to prevent loss of transplanted organs provided that
adequate treatment is available (Mao 
 
et al
 
., 2007).
However, we should not forget that the best policy is
prevention of antibody formation. HLA matching, and
especially matching of donor and recipient for the antibody
epitopes present on the HLA molecules (Dankers 
 
et al
 
.,
2004), will prevent that many retransplant candidates
will ﬁnally end up as highly sensitized patients with
very extensive antibody proﬁles in the current solid-phase
assays.
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